Neha Patil (Editor)


Updated on
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Routes of administration  Oral
CAS Number  379231-04-6
ChemSpider  8477917
Molar mass  542.025 g/mol
Legal status  Investigational
PubChem CID  10302451
Formula  C27H32ClN5O5
Saracatinib wwwreagentsdirectcommediacatalogproductcache

Saracatinib from selleckchem com

Saracatinib (AZD-0530) is an experimental drug being developed by AstraZeneca. It acts as a dual kinase inhibitor, with selective actions as a Src inhibitor and a Bcr-Abl tyrosine-kinase inhibitor. It was originally under development for the treatment of cancer, but while it appeared promising in animal studies and was well tolerated in humans, it failed to show sufficient efficacy in cancer patients and was ultimately not developed further for this application. However saracatinib has subsequently been researched for other applications such as Alzheimer's disease. AZD0530 is an inhibitor of Src and Abl family kinases1. It has been developed as treatment for malignancies because these kinases play a role in tumor invasion and proliferation. However, the Src family kinases (SFKs) are highly expressed in brain and have major effects on synaptic plasticity2. Moreover, the investigators have recently shown that a specific SFK, namely Fyn, is aberrantly activated by specific conformations of the Amyloid Beta (Aß) peptide from Alzheimer's disease (AD). Genetic deletion of Fyn rescues AD deficits in preclinical models. This clinical trial will test the potential benefit of AZD0530 for Alzheimer's disease modification. and schizophrenia.


Saracatinib Wikipedia